TIR:血糖评估与胰岛素治疗的新靶标  

Time in Range:New Target for Glucose Assessment and Insulin Therapy

作　　者：陆菊明[1] LU Juming(Department of Endocrinology,The First Medical Center of PLA General Hospital,Beijing 100853,China.)

机构地区：[1]解放军总医院第一医学中心内分泌科,北京100853

出　　处：《药品评价》2020年第20期1-3,共3页Drug Evaluation

摘　　要：血糖变异性被大量研究证实与糖尿病患者的血糖管理水平和临床预后显著相关,而目标范围内时间(TIR)作为动态血糖监测(CGM)报告中评估短期血糖变异性的关键指标之一,在近年来也逐渐引起临床重视。综合多维度的血糖管理成为糖尿病患者更为优化的治疗模式。A large number of studies have confirmed that glycemic variability is significantly correlated with blood glucose management and clinical prognosis in diabetes.As one of the key indicators for evaluating short-term glycemic variability in CGM reports,Time in Range(TIR)has gradually attracted clinical attention in recent years.Comprehensive multi-dimensional blood glucose management has become a more optimal treatment mode for diabetes.

关 键 词：共识 糖尿病 血糖变异性 TIR 德谷胰岛素 

分 类 号：R977.15[医药卫生—药品]